X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs DR. REDDYS LAB - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES DR. REDDYS LAB PIRAMAL ENTERPRISES/
DR. REDDYS LAB
 
P/E (TTM) x 36.3 29.0 125.1% View Chart
P/BV x 3.0 2.8 106.1% View Chart
Dividend Yield % 0.8 1.0 84.9%  

Financials

 PIRAMAL ENTERPRISES   DR. REDDYS LAB
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-17
DR. REDDYS LAB
Mar-17
PIRAMAL ENTERPRISES/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs2,0953,397 61.7%   
Low Rs1,0252,560 40.0%   
Sales per share (Unadj.) Rs492.8856.5 57.5%  
Earnings per share (Unadj.) Rs72.678.0 93.1%  
Cash flow per share (Unadj.) Rs94.7139.9 67.7%  
Dividends per share (Unadj.) Rs21.0020.00 105.0%  
Dividend yield (eoy) %1.30.7 200.5%  
Book value per share (Unadj.) Rs862.5739.8 116.6%  
Shares outstanding (eoy) m172.56165.74 104.1%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.23.5 91.0%   
Avg P/E ratio x21.538.2 56.3%  
P/CF ratio (eoy) x16.521.3 77.4%  
Price / Book Value ratio x1.84.0 44.9%  
Dividend payout %28.925.7 112.8%   
Avg Mkt Cap Rs m269,194493,632 54.5%   
No. of employees `0004.022.7 17.7%   
Total wages/salary Rs m17,93931,068 57.7%   
Avg. sales/employee Rs Th21,190.36,259.0 338.6%   
Avg. wages/employee Rs Th4,470.11,369.8 326.3%   
Avg. net profit/employee Rs Th3,120.0569.7 547.7%   
INCOME DATA
Net Sales Rs m85,037141,961 59.9%  
Other income Rs m2,3381,715 136.3%   
Total revenues Rs m87,374143,676 60.8%   
Gross profit Rs m34,99124,722 141.5%  
Depreciation Rs m3,81710,266 37.2%   
Interest Rs m20,310634 3,203.4%   
Profit before tax Rs m13,20215,537 85.0%   
Minority Interest Rs m1,6990-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m-1000-   
Tax Rs m2,2812,965 76.9%   
Profit after tax Rs m12,52012,921 96.9%  
Gross profit margin %41.117.4 236.3%  
Effective tax rate %17.319.1 90.5%   
Net profit margin %14.79.1 161.8%  
BALANCE SHEET DATA
Current assets Rs m87,59096,837 90.5%   
Current liabilities Rs m185,57884,199 220.4%   
Net working cap to sales %-115.28.9 -1,294.4%  
Current ratio x0.51.2 41.0%  
Inventory Days Days3173 42.3%  
Debtors Days Days4898 48.7%  
Net fixed assets Rs m108,523102,552 105.8%   
Share capital Rs m345829 41.6%   
"Free" reserves Rs m148,481121,792 121.9%   
Net worth Rs m148,826122,621 121.4%   
Long term debt Rs m144,9575,449 2,660.2%   
Total assets Rs m482,394218,165 221.1%  
Interest coverage x1.725.5 6.5%   
Debt to equity ratio x1.00 2,191.8%  
Sales to assets ratio x0.20.7 27.1%   
Return on assets %6.86.2 109.5%  
Return on equity %8.410.5 79.8%  
Return on capital %12.012.9 92.7%  
Exports to sales %054.6 0.0%   
Imports to sales %09.4 0.0%   
Exports (fob) Rs mNA77,520 0.0%   
Imports (cif) Rs mNA13,274 0.0%   
Fx inflow Rs m15,00181,670 18.4%   
Fx outflow Rs m5,15026,355 19.5%   
Net fx Rs m9,85155,315 17.8%   
CASH FLOW
From Operations Rs m-100,39321,444 -468.2%  
From Investments Rs m-24,202-18,404 131.5%  
From Financial Activity Rs m135,705-3,692 -3,675.6%  
Net Cashflow Rs m11,110-1,144 -971.1%  

Share Holding

Indian Promoters % 52.9 25.5 207.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 5.4 74.1%  
FIIs % 26.6 35.3 75.4%  
ADR/GDR % 0.0 18.5 -  
Free float % 16.5 15.3 107.8%  
Shareholders   93,274 75,885 122.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   BIOCON LTD  CADILA HEALTHCARE  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare PIRAMAL ENTERPRISES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Red; PSU & Energy Stocks Decline(01:30 pm)

Indian share markets continued to trade in red during the noon session weak Asian markets. PSU stocks and energy stocks are witnessing majority of the selling activity.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Feb 22, 2018 02:21 PM

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS